TrialESMO open2024

A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).

A M Di Giacomo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.